Jon Dubrow and Gregory Heltzer wrote this bylined article describing how government antitrust regulators have recently rejected surgical divestitures or other proposed remedies in business combinations. Recent failed deals show that the DOJ and FTC “have continued to raise the bar for what they view as acceptable remedies and buyers,” the authors wrote.
